Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Pleural Mesothelioma | Research article

Physician requests by patients with malignant pleural mesothelioma in Japan

Authors: Yasuko Nagamatsu, Isao Oze, Keisuke Aoe, Katsuyuki Hotta, Katsuya Kato, Junko Nakagawa, Keiko Hara, Takumi Kishimoto, Nobukazu Fujimoto

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

Malignant pleural mesothelioma (MPM) is a fatal and rare disease that is caused by the inhalation of asbestos. Treatment and care requests made by MPM patients to their physicians were collected and analyzed.

Methods

This cross-sectional survey was part of a larger study (N = 133) regarding the quality of life of MPM patients. Specific responses to two open-ended questions related to patients’ requests regarding treatment and care were quantified, analyzed and divided into categories based on content.

Results

Responses (N = 217) from MPM patients (N = 73) were categorized into 24 subcategories and then abstracted into 6 categories. The majority of requests were related to patient-physician communication. Patients wanted clear and understandable explanations about MPM and wanted their physician to deliver treatment based on the patient’s perspective by accepting and empathizing with their anxiety and pain. Patients expected physicians to be dedicated to their care and establish an improved medical support system for MPM patients.

Conclusion

Patients with MPM had a variety of unmet needs from their physicians. Physicians who provide care to MPM patients should receive training in both communication skills and stress management. A multidisciplinary care system that includes respiratory and palliative care for MPM patients should be established.
Appendix
Available only for authorised users
Literature
1.
Rong Y, Luo X, Zhang Z, Cui X, Liu Y, Chen W. Occupational exposure to asbestos and cardiovascular related diseases: a meta-analysis. Prev Med Rep. 2015;2:920–6.CrossRef
2.
3.
Murayama T, Takahashi K, Natori Y, Kurumatani N. Estimation of future mortality from flexural malignant mesothelioma in Japan based on an age-cohort model. Am J Ind Med. 2006;49:1–7.CrossRef
4.
Aisner J. Current approach to malignant mesothelioma of the pleura. Chest. 1995;107:332S–44S.CrossRef
5.
Dozier J, Zheng H, Adusumilli PS. Immunotherapy for malignant pleural mesothelioma: current status and future directions. Transl Lung Cancer Res. 2017;6:315–24.CrossRef
6.
Ahmedzai SH, Clayson H. Supportive and palliative care in mesothelioma. In: O’Byrne K, Rusch V, editors. Malignant pleural mesothelioma. New York: Oxford University Press; 2006. p. 403–33.
7.
Clayson H, Seymour J, Noble B. Mesothelioma from the patient’s perspective. Hematol Oncol Clin North Am. 2005;19:1175–90.CrossRef
8.
Knudsen N, Block K, Schulman S. Malignant pleural mesothelioma. Oncol Nurs Forum. 1989;16:845–51.PubMed
9.
Guglielmucci F, Franzoi IG, Bonafede M, Borgogno FV, Grosso F, Granieri A. “The less I think about it, the better I feel”: a thematic analysis of the subjective experience of malignant mesothelioma patients and their caregivers. Front Psychol. 2018;9:205.CrossRef
10.
Nagamatsu Y, Horiuchi S, Natori Y. The stages and difficulties of patients with malignant pleural mesothelioma. J Human Care Stud. 2012;12:69–81. (In Japanese).
11.
Furuya S, Takahashi K. Experience of Japan in achieving a total ban on asbestos. Int J Environ Res Public Health. 2017;14:E1261.CrossRef
12.
Hughes N, Arber A. The lived experience of patients with pleural mesothelioma. Int J Palliat Nurs. 2008;14:66–71.CrossRef
13.
Clayson H. Suffering with mesothelioma: concepts and contexts. Eur J Palliat Care. 2003;11:251–4.
14.
Novello S, Pinto C, Torri V, Porcu L, Di Maio M, Tiseo M, et al. The third Italian consensus conference for malignant pleural mesothelioma: state of the art and recommendations. Crit Rev Oncol Hematol. 2016;104:9–20.CrossRef
15.
16.
Graneheim UH, Lundman B. Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthiness. Nurse Educ Today. 2004;24:105–12.CrossRef
17.
Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15:1277–88.CrossRef
18.
Ishikawa H, Takayama T, YamazakI Y, Seki Y, Katsumata N. Physician–patient communication and patient satisfaction in Japanese cancer consultations. Soc Sci Med. 2002;55:301–11.CrossRef
19.
Feudtner C. Collaborative communication in pediatric palliative care: a foundation for problem-solving and decision-making. Pediatr Clin N Am. 2007;54:583–607.CrossRef
20.
Miyage K, Isa M. Distrust of doctors in medical treatment, and communication seen from the viewpoint of patients. Kyushu Comm Stud. 2012;10:14–36.
21.
Moore S, Darlison L, Tod AM. Living with mesothelioma. A literature review. Eur J Cancer Care (Engl). 2010;19:458–68.CrossRef
22.
Katagiri K, Komatsu H, Iba N, Tonosaki A, Minamikawa M, Sakai Y, et al. Difficulty, demand and coping in people with cancer. J Japanese Soc Cancer Nurs. 2015;15:68–74 (In Japanese].
23.
Takayama T, Yamazaki Y, Katsumata N. Relationship between outpatients’ perceptions of physicians’ communication styles and patients’ anxiety levels in a Japanese oncology setting. Social Sci Med. 2001;53:1335–50.CrossRef
24.
Ohori Y, Sato N. The quality of life of the patients having breast cancer recurrence: contents of the speech from three patients building up life actively. J Japanese Soc Cancer Nurs. 2015;17:35–41 (in Japanese).
25.
Molleman E, Krabbendam PJ, Annyas AA, Koops HS, Sleijfer DT, Vermey A. The significance of the doctor-patient relationship in coping with cancer. Soc Sci Med. 1984;18:475–80.CrossRef
26.
Lee SF, O'Connor MM, Chapman Y, Hamilton V, Francis K. A very public death: dying of mesothelioma and asbestos-related lung cancer (M/ARLC) in the Latrobe Valley, Victoria, Australia. Rural Remote Health. 2009;9:1183.PubMed
27.
Dooley JJ, Wilson JP, Anderson VA. Stress and depression of facing death: investigation of psychological symptoms in patients with mesothelioma. Aust J Psychol. 2010;62:160–8.CrossRef
28.
Yanagihara K. Factors in the process and structure of the “will determination” by families of cancer patients–focusing on the social work at “great change” stage and terminal stage. Bull Japan Lutheran Coll. 2008;42:77–96 (abstract in English).
29.
Woolhouse I, Bishop L, Darlison L, De Fonseka D, Edey A, Edwards J, et al. British Thoracic Society guideline for the investigation and management of malignant pleural mesothelioma. Thorax. 2018;73(Suppl 1):i1–i30.CrossRef
30.
Miyashita M, Morita T, Sato K, Tsuneto S, Shima Y. A nationwide survey of quality of end-of-life cancer care in designated cancer centers, inpatient palliative care units, and home hospices in Japan: the J-HOPE study. J Pain Symptom Manag. 2015;50:38–47.CrossRef
31.
Nagamatsu Y, Horiuchi S, Natori Y. Difficulties faced by nurses in caring for patients with malignant pleural mesothelioma. J Human Care Stud. 2012;13:1–13 (in Japanese).
32.
Budych K, Helms T, Schultz C. How do patients with rare diseases experience the medical encounter: exploring role behavior and its impact on patient-physician interaction. Health Policy. 2012;105:154–64.CrossRef
Metadata
Title
Physician requests by patients with malignant pleural mesothelioma in Japan
Authors
Yasuko Nagamatsu
Isao Oze
Keisuke Aoe
Katsuyuki Hotta
Katsuya Kato
Junko Nakagawa
Keiko Hara
Takumi Kishimoto
Nobukazu Fujimoto
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5591-7

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue

Study protocol

The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma

Research article

Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigation

Case report

Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case report

Research article

Development of nomograms for prognostication of patients with primary soft tissue sarcomas of the trunk and extremity: report from the Bone and Soft Tissue Tumor Registry in Japan

Research article

The long-term survival of patients with III-IVb stage nasopharyngeal carcinoma treated with IMRT with or without Nimotuzumab: a propensity score-matched analysis

Research article

Prevalence of germline mutations in the TP53 gene in patients with early-onset breast cancer in the Mexican population
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits